52-Week results from IXORA-S: a randomized head-to-head trial of ixekizumab and ustekinumab in patients with moderate-to-severe plaque psoriasis

被引：0
|
作者：
Paul, C. [1 ]
van de Kerkhof, P. [2 ]
Dutronc, Y. [3 ]
Henneges, C. [3 ]
Dossenbach, M. [3 ]
Hollister, K. [3 ]
Reich, K. [4 ,5 ]
机构：
[1] Paul Sabatier Univ, CHU, Dermatol, Toulouse, France
[2] Radboud Univ Nijmegen, Med Ctr, Dept Dermatol, Nijmegen, Netherlands
[3] Eli Lilly & Co, Indianapolis, IN 46285 USA
[4] Dermatol Hamburg, Hamburg, Germany
[5] SCIderm Res Inst, Hamburg, Germany
来源：
BRITISH JOURNAL OF DERMATOLOGY | 2017年 / 177卷 / 05期
关键词：
D O I：
暂无
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
P094
引用
收藏
页码：E293 / E293
页数：1
相关论文
共 50 条
  • [1] Ixekizumab and Ustekinumab Efficacy in Nail Psoriasis in Patients with Moderate-to-Severe Psoriasis: 52-Week Results from a Phase 3, Head-to-Head Study (IXORA-S)
    Wasel, Norman
    Thaci, Diamant
    French, Lars E.
    Conrad, Curdin
    Dutronc, Yves
    Gallo, Gaia
    Berggren, Lovisa
    Lacour, Jean-Philippe
    DERMATOLOGY AND THERAPY, 2020, 10 (04) : 663 - 670
  • [2] Ixekizumab and Ustekinumab Efficacy in Nail Psoriasis in Patients with Moderate-to-Severe Psoriasis: 52-Week Results from a Phase 3, Head-to-Head Study (IXORA-S)
    Norman Wasel
    Diamant Thaçi
    Lars E. French
    Curdin Conrad
    Yves Dutronc
    Gaia Gallo
    Lovisa Berggren
    Jean-Philippe Lacour
    Dermatology and Therapy, 2020, 10 : 663 - 670
  • [3] Comparison of ixekizumab with ustekinumab in moderate-to-severe psoriasis: 24-week results from IXORA-S, a phase III study
    Reich, K.
    Pinter, A.
    Lacour, J. P.
    Ferrandiz, C.
    Micali, G.
    French, L. E.
    Lomaga, M.
    Dutronc, Y.
    Henneges, C.
    Wilhelm, S.
    Hartz, S.
    Paul, C.
    BRITISH JOURNAL OF DERMATOLOGY, 2017, 177 (04) : 1014 - 1023
  • [4] Efficacy and safety of ixekizumab (IXE) compared to ustekinumab (UST) in patients with moderate-to-severe plaque psoriasis: A randomised head-to-head trial
    Burkhardt, N.
    Reich, K.
    Lomaga, M.
    Henneges, C.
    Dossenbach, M.
    Wilhelm, S.
    Paul, C.
    AUSTRALASIAN JOURNAL OF DERMATOLOGY, 2017, 58 : 43 - 43
  • [5] Ixekizumab treatment results in more rapid clinical improvements in patients with moderate-to-severe psoriasis compared with ustekinumab: Results from the IXORA-S trial
    Pinter, Andreas
    Amato, David
    Burge, Russel
    Dong, Yan
    Zhu, Baojin
    Shrom, David
    Gallo, Gaia
    Lomaga, Mark
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2019, 81 (04) : AB230 - AB230
  • [6] An Analysis of Patient-reported Outcomes in IXORA-S: Comparing Ixekizumab and Ustekinumab over 52 Weeks in Moderate-to-severe Psoriasis
    Puig, Lluis
    Lomaga, Mark
    Hollister, Kristin
    Dutronc, Yves
    Berggren, Lovisa
    van de Kerkhof, Peter C. M.
    ACTA DERMATO-VENEREOLOGICA, 2020, 100 : 1 - 7
  • [7] A head-to-head comparison of ixekizumab vs. guselkumab in patients with moderate-to-severe plaque psoriasis: 24-week efficacy and safety results from a randomized, double-blinded trial
    Blauvelt, A.
    Leonardi, C.
    Elewski, B.
    Crowley, J. J.
    Guenther, L. C.
    Gooderham, M.
    Langley, R. G.
    Vender, R.
    Pinter, A.
    Griffiths, C. E. M.
    Tada, Y.
    Elmaraghy, H.
    Lima, R. G.
    Gallo, G.
    Renda, L.
    Burge, R.
    Park, S. Y.
    Zhu, B.
    Papp, K.
    BRITISH JOURNAL OF DERMATOLOGY, 2021, 184 (06) : 1047 - 1058
  • [8] A Head-to-Head Comparison of Ixekizumab Versus Guselkumab in Patients with Moderate-to-Severe Plaque Psoriasis: 12-Week Efficacy, Safety, and Speed of Response from a Randomized, Double-Blinded Trial
    Blauvelt, Andrew
    Papp, Kim
    Jarell, Abel
    Reich, Kristian
    Gottlieb, Alice
    Lima, Renata Gontijo
    Elmaraghy, Hany
    Gallo, Gaia
    Renda, Lisa
    Park, So Young
    Bagel, Jerry
    JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2020, 18 : 16 - 17
  • [9] Improvement in touch avoidance in patients with genital psoriasis treated with ixekizumab: 52-week results of a phase 3 clinical trial in patients with moderate-to-severe genital psoriasis (IXORA-Q)
    Soung, Jennifer
    Cather, Jennifer Clay
    Gooderham, Melinda
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2022, 87 (03) : AB69 - AB69
  • [10] Secukinumab treatment demonstrated high efficacy and safety in pediatric patients with moderate-to-severe plaque psoriasis: 52-week results from a randomized trial
    Magnolo, Nina
    Kingo, Kulli
    Laquer, Vivian
    Browning, John
    Reich, Adam
    Szepietowski, Jacek C.
    Keefe, Deborah
    Mazur, Rafal
    Ghelani, Prayashi
    Forrer, Pascal
    Patekar, Manmath
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2021, 85 (03) : AB119 - AB119
12345